SG11202108099WA - LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF - Google Patents
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOFInfo
- Publication number
- SG11202108099WA SG11202108099WA SG11202108099WA SG11202108099WA SG11202108099WA SG 11202108099W A SG11202108099W A SG 11202108099WA SG 11202108099W A SG11202108099W A SG 11202108099WA SG 11202108099W A SG11202108099W A SG 11202108099WA SG 11202108099W A SG11202108099W A SG 11202108099WA
- Authority
- SG
- Singapore
- Prior art keywords
- tgfβ
- specific inhibitors
- ltbp complex
- ltbp
- complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798927P | 2019-01-30 | 2019-01-30 | |
| PCT/US2020/015915 WO2020160291A2 (en) | 2019-01-30 | 2020-01-30 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108099WA true SG11202108099WA (en) | 2021-08-30 |
Family
ID=69423073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108099WA SG11202108099WA (en) | 2019-01-30 | 2020-01-30 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11214614B2 (en) |
| EP (1) | EP3689905A3 (en) |
| JP (1) | JP2022524281A (en) |
| KR (1) | KR20210121174A (en) |
| CN (1) | CN113677711A (en) |
| AR (1) | AR117918A1 (en) |
| AU (1) | AU2020216177A1 (en) |
| BR (1) | BR112021015056A2 (en) |
| CA (1) | CA3128042A1 (en) |
| CL (1) | CL2021001993A1 (en) |
| CO (1) | CO2021010062A2 (en) |
| CR (1) | CR20210416A (en) |
| DO (1) | DOP2021000161A (en) |
| EA (1) | EA202192130A1 (en) |
| IL (1) | IL285076A (en) |
| MA (1) | MA54845A (en) |
| MX (1) | MX2021009175A (en) |
| PE (1) | PE20220279A1 (en) |
| SG (1) | SG11202108099WA (en) |
| TW (1) | TW202043267A (en) |
| WO (1) | WO2020160291A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021015056A2 (en) | 2019-01-30 | 2022-01-11 | Scholar Rock Inc | Specific inhibitors of tgf-beta ltbp complexes and uses thereof |
| AR120077A1 (en) | 2019-08-28 | 2022-02-02 | Chugai Pharmaceutical Co Ltd | LATENT ANTI-TGF-b 1 ANTIBODIES AND METHODS OF USE |
| EP4087649A1 (en) * | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgfbeta inhibitors and use thereof |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| WO2022271867A1 (en) * | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0564531T3 (en) | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
| ES2287206T3 (en) | 1991-03-01 | 2007-12-16 | Dyax Corporation | PROCESS FOR THE DEVELOPMENT OF MINI-PROTEINS OF UNION. |
| IE921169A1 (en) | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
| PT1024191E (en) | 1991-12-02 | 2008-12-22 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP1674480A4 (en) | 2003-09-04 | 2007-06-20 | Riken | Antibody recognizing tgf-beta activation controlling region section |
| CN101163502A (en) | 2005-02-08 | 2008-04-16 | 根茨美公司 | Antibodies to tgf-beta |
| CN101163719A (en) | 2005-04-22 | 2008-04-16 | 伊莱利利公司 | Tgf beta 1 specific antibodies |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
| WO2011102483A1 (en) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | HUMAN LAP TGF-β BINDING ANTIBODY |
| US8569462B2 (en) * | 2011-06-03 | 2013-10-29 | Xoma Technology Ltd. | Antibodies specific for TGF-beta and methods for treating thereof |
| EP2916867A4 (en) | 2012-11-06 | 2016-10-05 | Scholar Rock Inc | Compositions and methods for modulating cell signaling |
| EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| CR20170326A (en) | 2014-12-19 | 2017-08-22 | Chugai Pharmaceutical Co Ltd | ANTIMIOSTATINE ANTIBODIES, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS, AND METHODS OF USE |
| CN108136001B (en) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | Treatment of cancer using TGF-beta inhibitors and PD-1 inhibitors |
| CA3036652A1 (en) * | 2015-09-15 | 2017-03-23 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| SG11201807176XA (en) * | 2016-03-11 | 2018-09-27 | Scholar Rock Inc | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF |
| EP4218804A3 (en) | 2016-06-13 | 2023-09-13 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
| SG11201900200XA (en) | 2016-07-14 | 2019-02-27 | Scholar Rock Inc | Tgfb antibodies, methods, and uses |
| US10375984B2 (en) | 2016-07-18 | 2019-08-13 | R.J. Reynolds Tobacco Company | Nonwoven composite smokeless tobacco product |
| KR20230125859A (en) | 2016-08-12 | 2023-08-29 | 메르크 파텐트 게엠베하 | Combination therapy for cancer |
| TW201811827A (en) * | 2016-09-05 | 2018-04-01 | 日商中外製藥股份有限公司 | Anti-TGF-beta 1 antibodies and methods of use |
| WO2018129329A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
| AU2018205233A1 (en) | 2017-01-07 | 2019-07-11 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted TGFβ inhibition |
| EA201991729A1 (en) | 2017-01-20 | 2019-12-30 | Санофи | ANTIBODIES TO TGF-BETA AND THEIR APPLICATION |
| AU2018228435A1 (en) | 2017-03-02 | 2019-10-03 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
| MA49690A (en) * | 2017-07-28 | 2021-05-19 | Scholar Rock Inc | SPECIFIC INHIBITORS OF THE TGF-BETA 1 LTBP COMPLEX AND THEIR USES |
| WO2020014460A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF |
| WO2020014473A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | TGFβ1 INHIBITORS AND USE THEREOF |
| BR112021015056A2 (en) | 2019-01-30 | 2022-01-11 | Scholar Rock Inc | Specific inhibitors of tgf-beta ltbp complexes and uses thereof |
-
2020
- 2020-01-30 BR BR112021015056A patent/BR112021015056A2/en unknown
- 2020-01-30 MA MA054845A patent/MA54845A/en unknown
- 2020-01-30 TW TW109102916A patent/TW202043267A/en unknown
- 2020-01-30 SG SG11202108099WA patent/SG11202108099WA/en unknown
- 2020-01-30 CN CN202080026577.3A patent/CN113677711A/en active Pending
- 2020-01-30 PE PE2021001254A patent/PE20220279A1/en unknown
- 2020-01-30 CA CA3128042A patent/CA3128042A1/en active Pending
- 2020-01-30 WO PCT/US2020/015915 patent/WO2020160291A2/en active Application Filing
- 2020-01-30 EP EP20154732.0A patent/EP3689905A3/en active Pending
- 2020-01-30 MX MX2021009175A patent/MX2021009175A/en unknown
- 2020-01-30 JP JP2021543179A patent/JP2022524281A/en active Pending
- 2020-01-30 EA EA202192130A patent/EA202192130A1/en unknown
- 2020-01-30 AU AU2020216177A patent/AU2020216177A1/en active Pending
- 2020-01-30 AR ARP200100240A patent/AR117918A1/en unknown
- 2020-01-30 CR CR20210416A patent/CR20210416A/en unknown
- 2020-01-30 KR KR1020217027487A patent/KR20210121174A/en active Search and Examination
- 2020-08-19 US US16/997,438 patent/US11214614B2/en active Active
-
2021
- 2021-07-22 IL IL285076A patent/IL285076A/en unknown
- 2021-07-29 CO CONC2021/0010062A patent/CO2021010062A2/en unknown
- 2021-07-29 CL CL2021001993A patent/CL2021001993A1/en unknown
- 2021-07-30 DO DO2021000161A patent/DOP2021000161A/en unknown
- 2021-11-19 US US17/530,786 patent/US11365245B2/en active Active
-
2022
- 2022-05-17 US US17/746,325 patent/US20220363741A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR117918A1 (en) | 2021-09-01 |
| MX2021009175A (en) | 2021-09-14 |
| TW202043267A (en) | 2020-12-01 |
| WO2020160291A2 (en) | 2020-08-06 |
| CL2021001993A1 (en) | 2022-04-08 |
| CR20210416A (en) | 2021-09-14 |
| US11214614B2 (en) | 2022-01-04 |
| EP3689905A2 (en) | 2020-08-05 |
| KR20210121174A (en) | 2021-10-07 |
| WO2020160291A9 (en) | 2020-10-15 |
| US11365245B2 (en) | 2022-06-21 |
| WO2020160291A3 (en) | 2020-09-10 |
| CA3128042A1 (en) | 2020-08-06 |
| IL285076A (en) | 2021-09-30 |
| EP3689905A3 (en) | 2021-02-24 |
| DOP2021000161A (en) | 2021-09-15 |
| PE20220279A1 (en) | 2022-02-25 |
| US20210047396A1 (en) | 2021-02-18 |
| CO2021010062A2 (en) | 2021-08-09 |
| BR112021015056A2 (en) | 2022-01-11 |
| AU2020216177A1 (en) | 2021-09-23 |
| US20220064276A1 (en) | 2022-03-03 |
| EA202192130A1 (en) | 2021-12-28 |
| MA54845A (en) | 2021-09-29 |
| CN113677711A (en) | 2021-11-19 |
| JP2022524281A (en) | 2022-05-02 |
| US20220363741A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285076A (en) | Ltbp complex-specific inhibitors of tgfβ and uses thereof | |
| IL288381A (en) | Tead inhibitors and uses thereof | |
| IL288384A (en) | Tead inhibitors and uses thereof | |
| IL287940A (en) | Fgfr inhibitors and methods of use thereof | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| IL284508A (en) | Irreversible inhibitors of menin-mll interaction | |
| IL281939A (en) | Inhibitors of vap-1 | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL288747A (en) | Inhibitors of integrated stress response pathway | |
| IL285697A (en) | Inhibitors of integrated stress response pathway | |
| IL287973A (en) | Acss2 inhibitors and methods of use thereof | |
| IL276711A (en) | Arginase inhibitors and methods of use thereof | |
| IL279151A (en) | Inhibitors of integrated stress response pathway | |
| SG11202112666YA (en) | Methods of characterizing and utilizing agent-condensate interactions | |
| IL289914A (en) | Enzyme inhibitors | |
| IL289473A (en) | Transgenic mammals and methods of use | |
| IL286622A (en) | Prmt5 inhibitors and uses thereof | |
| IL289863A (en) | Enzyme inhibitors | |
| SG11202103131UA (en) | Inhibitors of vap-1 | |
| IL289778A (en) | Enzyme inhibitors | |
| IL289783A (en) | Enzyme inhibitors | |
| IL280924A (en) | Arginase inhibitors and methods of use thereof |